Latest News of IOVA
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
By Yahoo! Finance |
12 hours ago
Iovance Biotherapeutics (NASDAQ: IOVA) is a promising biotech stock due to its unique cell therapy for melanoma, Amtagvi. However, profitability may be a long-term goal, and the company faces challeng...
Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock
By Yahoo! Finance |
2 days ago
Insider Monkey compiled a list of the 10 worst cancer stocks according to short sellers, focusing on Iovance Biotherapeutics, Inc. Despite being heavily shorted, the company showed optimistic Q2 earni...
Giovanni's, London: 'Exactly what you want it to be' - restaurant review
By The Guardian |
1 week ago
Giovanni's, a long-standing Italian restaurant in London, continues to delight with traditional dishes and a nostalgic atmosphere. Owned by the Ragona family since 1952, it maintains its charm with cl...
-
Betis sign Tottenham's Giovani Lo Celso on four-year deal
By The New York Times | 2 weeks agoGiovani Lo Celso has returned to Real Betis from Tottenham Hotspur on a permanent deal. After a loan spell at Villarreal, the Argentina international has signed a four-year contract with Betis....
-
Flagship, Quotient and Pfizer link on cardiovascular and renal disease
By Yahoo! Finance | 2 weeks agoFlagship Pioneering and Quotient Therapeutics partner with Pfizer to discover new therapeutic targets for cardiovascular and renal diseases. They will analyze somatic mutations in diseased tissue to d...
-
Positive Results For A New RNA Therapy For Cardiovascular Disease
By Forbes | 1 month agoRNA interference gene therapies like inclisiran show promise in managing cardiovascular disease by reducing LDL cholesterol levels, potentially revolutionizing treatment. These therapies target harmfu...
-
Industry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue Forecasts
By Yahoo! Finance | 1 month agoIovance Biotherapeutics (NASDAQ:IOVA) saw significant upgrades in revenue forecasts, with analysts predicting a 396% increase by 2024. Share price surged 36% in 7 days. Analysts expect accelerated gro...
-
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 1 month agoIovance Biotherapeutics is a biotechnology company in the US that develops and commercializes cell therapies for treating melanoma and other solid tumor cancers. They offer autologous T cell immunothe...
-
Super Bowl hero Jacoby Jones died of cardiovascular disease, medical examiner says
By Fox News | 1 month agoJacoby Jones, a former Baltimore Ravens player and Super Bowl champion, passed away from long-term high blood pressure-related disease. Known for his playoff heroics, Jones will be remembered for his ...
-
Dunkin' debuts new iced coffee drinks in collaboration with celebrity chef Nick DiGiovanni
By USA Today | 1 month agoDunkin' has collaborated with chef Nick DiGiovanni to launch "The Chef Nick Menu," featuring 4 new iced coffee drinks available through their mobile app....
-
Here's Why Iovance Biotherapeutics (IOVA) Declined in Q2
By Yahoo! Finance | 1 month agoArtisan Partners released its Q2 2024 investor letter for the Artisan Small Cap Fund, reporting returns and insights on the US economy. Highlighted stock pick was Iovance Biotherapeutics, Inc. (NASDAQ...
-
NIH-funded trial finds HIV drug abacavir linked to higher cardiovascular risk
By Yahoo! Finance | 1 month agoNIH-funded REPRIEVE trial finds that HIV drug abacavir is associated with a higher risk of cardiovascular events. A daily statin regimen was shown to reduce MACE risk by over one-third. Further resear...
-
From MasterChef To YouTube Master: Nick DiGiovanni's Rise To Stardom
By Forbes | 1 month agoNick DiGiovanni, a rising star in the culinary world, gained fame from MasterChef to becoming a successful content creator. With a goal to surpass Gordon Ramsay's YouTube subscribers, his journey is s...
-
Insider Sale: Director Vincentelli Sangiovanni Sells Shares of Cadence Design Systems Inc (CDNS)
By Yahoo! Finance | 1 month agoVincentelli Sangiovanni, a Director at Cadence Design Systems Inc, sold 1,500 shares at $314.57 each. The company focuses on EDA software. With 46,551 shares left, Sangiovanni has sold 43,800 shares o...
-
Cardurion closes $260m in Series B to develop cardiovascular pipeline
By Yahoo! Finance | 1 month agoCardurion Pharmaceuticals, a US cardiology biotech, secured $260m in Series B funding to advance its drug pipeline, focusing on heart failure and genetic arrhythmic diseases. The company plans to expa...